Urothelial Cancer

Check out some of the top oncology news and trends of the week.

Matthew Galsky, MD, discusses the emergence of ICIs the neoadjuvant setting of bladder cancer.

Matthew Galsky, MD, discusses the standing of immune checkpoint inhibitors in bladder cancer.

Matthew Galsky, MD, disusses how the treatment paradigm of bladder cancer has shifted over time.

OncLive spoke with urothelial cancer experts during Bladder Cancer Awareness Month to understand the current and future treatment landscape.

Durvalumab plus BCG maintained overall survival and quality of life in high-risk NMIBC at 5 years.

At the 2026 ASCO Annual Meeting, 3.5-year follow-up findings from the phase 3 EV-302/KEYNOTE-A39 study have been presented.

LY4052031 demonstrated promising clinical activity after disease progression on enfortumab vedotin in metastatic urothelial carcinoma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA has approved durvalumab in combination with BCG for the treatment of adult patients with BCG-naive, high-risk NMIBC.

OncLive spoke with experts in the field of GU oncology to gain their insights on the most notable presentations from the 2026 AUA Annual Meeting.

The CHMP granted a positive opinion to perioperative pembrolizumab/enfortumab vedotin as well as pembrolizumab and berahyaluronidase alfa in MIBC.

The FDA approved Dato-DXd for PD-1/PD-L1–ineligible triple-negative breast cancer, granted priority review to sevabertinib in HER2-mutant NSCLC, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

A supplemental BLA for nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with papillary-only disease is under review by the FDA.

Matthew Galsky, MD, discusses the present and future treatment landscape of MIBC during Bladder Cancer Awareness Month.

In an indirect comparison, NAI+BCG showed numerically higher, significantly longer responses and a trend toward greater bladder preservation vs nadofaragene.

The top 5 OncLive TV videos of the week cover insights in breast cancer, acute myeloid leukemia, bladder cancer, multiple myeloma, and melanoma.

The FDA approved T-DXd in early HER2+ breast cancer, adjuvant atezolizumab in MRD+ MIBC, and more.

Two doses of intravesical mitomycin-C administered before TURBT produced a 77% reduction in the risk of recurrence or death vs TURBT alone in NMIBC.

A biomarker analysis of SunRISe-4 found that high baseline TMB, GBD, and PD-L1 expression were associated with pathologic overall response to the regimen.

Durvalumab plus BCG induction and maintenance yielded an HR of 0.68 vs BCG alone for DFS in BCG-naive, high-risk non–muscle-invasive bladder cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Pembrolizumab plus BCG achieved a 92% 6-month complete response rate in very high-risk T1 bladder cancer with no progression to muscle-invasive disease.

The FDA approved adjuvant atezolizumab for muscle-invasive bladder cancer with circulating tumor DNA molecular residual disease.